In the search for effective drugs for the treatment of herpesviruses, considerable interest has been shown in the use of nucleoside analogues (5, 6, 26, 27) . 5-Iodo-2'-deoxyuridine (IUdR) (21), 9-f3-n-arabinofuranosyladenine (Ara-A) (6, 16) , and 1-f3-n-arabinofuranosylcytosine (Ara-C) (25) have been found to be effective to varying degrees in the treatment of infections due to herpesviruses. However, their high toxicity (9, 13, 25) , especially to rapidly proliferating cells (18, 19) , limits the usefulness of these nucleoside analogues in the treatment of viral infections. Recently, another nucleoside derivative, 5-methoxymethyl-2'-deoxyuridine (MMUdR), was synthesized (3) , and in preliminary experiments it showed antiviral activity against infectious bovine rhinotracheitis virus (14) . In this communication, we report the antiviral activity of MMUdR against other herpesviruses and vaccinia virus (VV) , and compare its antiviral activity and toxicity towards mammalian cells with IUdR, Ara-C, and Ara-A.
MATERIALS AND METHODS Drugs. MMUdR was synthesized (3) . Ara-C was kindly supplied by The Upjohn Co., Kalamazoo, Mich. IUdR and Ara-A were obtained from Sigma Chemical Co., St. Louis, Mo., and Phanstiehl Laboratories, Waukegan, Ill., respectively. The structures of the drugs used in these studies are illustrated in Fig. 1 .
Cell culture. The following cell lines used were: RK-13 (rabbit kidney), secondary feline embryo, HEP-2 (human epidermoid carcinoma no. 2), HeLA (human), and a secondary mouse embryo cell culture. The cells were cultured in Eagle minimal essential medium (GIBCO, Grand Island, N.Y.). Each liter of medium was supplemented with 2 mmol of glutamine (GIBCO no. 5034), 2.5 g of NaHCO3, 10 simultaneously. In combination antiviral chemotherapy experiments, each compound was dissolved at the appropriate concentration and both compounds were added together. The tissue culture plates were incubated at 37 C for 72 h, the culture fluid was removed, and the monolayers were washed with saline, fixed, stained with 1% gentian violet in 70% ethanol, and examined for virus plaques. The plaques were enumerated after magnification of plates, using an overhead projector or a dissecting microscope. The percentage of inhibition (calculated from reduction in the number of plaques) at each concentration of the compound was determined. In experiments where the inhibition of virus yield was determined, antiserum was not included in the overlay. Culture fluid was harvested daily and titrated to determine the amount of virus present (21) .
RESULTS
Comparison of antiviral potency of MMUdR, IUdR, Ara-C, and Ara-A against herpesviruses and vaccinia virus. In an initial series of experiments, several ether derivatives of 5-hydroxymethyl-2'-deoxyuridine (for structural fonnulae see reference 14) and 5-mercaptomethyl-2'-deoxyuridine were screened for antiviral activity against HSV-1 in HEP-2 cell cultures. MMUdR was markedly inhibitory, but the other derivatives investigated were without anti-HSV-1 activity. Because of its anti-HSV-1 activity, we decided to assess its antiviral activity against other herpesviruses. The results of a comparison of the spectrum of antiviral activity of MMUdR with other nucleoside derivatives (IUdR, Ara-C, and Ara-A) of known anti-herpesvirus activity are shown in Table 1 .
Whereas IUdR, Ara-A, and Ara-C were markedly inhibitory against all herpesviruses tested as well as against vaccinia virus, MMUdR appeared selectively antiviral against HSV-1 ( Table 1 ). Thus concentrations of 2 to 4 ,ug/ml were inhibitory to HSV-1, but levels of 128 ,ug/ml or greater were needed to inhibit feline rhinopneumonitis and vaccinia viruses. MMUdR failed to show antiviral activity against murine cytomegalovirus and equine rhinopneumonitis virus even at 256 ,ug/ml (highest dose tested).
In comparing the anti-HSV-1 activity of the four compounds on a molar basis, the spectrum of activity was IUdR > Ara-C > MMUdR > Ara-A, suggesting that IUdR may be the drug of choice to treat HSV-1. However, a comparison of the antiviral indexes (Table 2) revealed that MMUdR may be preferable over IUdR because of its lower toxicity and greater margin of safety. The antiviral index was defined as the minimum dose at which toxicity was observed microscopically divided by the dose that reduced plaque numbers by 50%. Effect of MMUdR on HSV-1 replication in different cell lines. The antiviral activity of MMUdR against HSV-1 was investigated by using different cell lines to determine whether the host cell affected the antiviral activity of MMUdR. Experiments with HeLa, Hep-2, and RK-13 cells showed a similar pattern of antiviral activity in all three lines (Fig. 2) . At 10 ,ug/ml there was a delay in the appearance of infectious virus, and virus titers at 72 h postinfection (p.i.) were markedly (2 to 3 logs), but not completely, reduced. At higher concentrations (25 or 50 ,ug/ml), infectious virus could not be detected at 72 h p.i.; however, by 96 h p.i. low levels (4 to 5 logs less than controls) became detectable. At present it is not known whether the virus produced after 3 days was due to the emergence of drug-resistant mutants or to decreased intracellular concentrations of MMUdR as a result of cellular metabolic activity converting MMUdR to other inactive metabolic products. In the presence of 100 ,g of MMUdR per ml, infectious virus production was totally inhibited (data not shown). MMUdR was devoid of toxicity to cells at this concentration (vide infra). These results suggest that MMUdR at lower concentrations (up to 50 ,ug/ml) has virostatic activity and at higher concentrations (100 ,ug/ml) has virocidal activity.
Effect of MMUdR on uninfected HEP-2 cells. The effect of MMUdR (50 ,ug/ml) and Ara-C (5 to 50 ,ug/ml) on the growth and plating density of HEP-2 cells is shown in Table 3 . Neither cell growth nor plating density was affected by 50 Ag of MMUdR per ml, a dose sufficient to completely prevent HSV-1 replication for 72 h. Furthermore, toxicity was not detectable by light microscopy and no decrease in cell viability was apparent even in cultures treated for 96 h with 500 pg of MMUdR per ml (highest concentration tested; data not shown). These results are consistent with the notion that in the concentration range of 2 to 50 Ag of MMUdR per ml, virus replication is inhibited directly rather than the inhibition being the result of drug toxicity to host cells.
In contrast to MMUdR, Ara-C was markedly more toxic. There was a significant decrease both in cell numbers and plating efficiency (Table 3) . By light microscopy, cell degeneration was evident at 72 h with as little as 4 ug of Ara-C per ml.
Susceptibility of MMUdR-treated HEP-2 cells to HSV-1 infection. The following experiments were undertaken to further support the hypothesis that the antiviral activity of MMUdR was directed at virus replication rather than acting by reducing virus replication indirectly as a result of its effect on the host cell. Confluent HEP-2 cells were treated with varying concentrations of MMUdR for 48 h. After washing of the monolayers to remove residual drug, the cells were infected with HSV-1. The results (Table 4) show that pretreatment of monolayers with MMUdR had no effect on subsequent HSV-1 replication. Plaque numbers of treated and control cultures were essentially identical at all intervals tested.
Inhibition of HSV replication by simultaneous treatment with combinations of two antiviral drugs. Therapeutic synergism achieved by the use of a combination of drugs has been of considerable value in the treatment of bacterial and neoplastic disease (9) (10) (11) 22) . The rationale for combination therapy is that host toxicity is reduced because lower levels of drugs can be used. Since all of the nucleoside analogues tested showed marked inhibitory activity against HSV-1, experiments were undertaken to determine the antiviral activity Fig. 3 and 4 . The combination of IUdR (0.5 ,ug/ml) and Ara-C (0.5 jig/ml) had a greater antiviral activity than did either compound alone (Fig. 3A) . Enhanced antiviral activity was also seen with the combination of Ara-A (2 or 4 ,ug/ml) and IUdR (0.5 ,ug/ml) (Fig. 3B) . In contrast, the antiviral activity remained essentially unchanged when Ara-A (4 p,g/ml) and Ara-C (0.5 ug/ml) were used together (Fig. 3C) . Combination of MMUdR (4 ,ug/ml) with IUdR, Ara-A, and Ara-C resulted in increased antiviral activity over the activity of these compounds used individually (Fig. 4) . DISCUSSION Herpesviruses are one of the groups of viruses that have not been successfully controlled by conventional immunization schemes. Consequently, their control by other means, such as antiviral chemotherapy, has been sought. Various drugs such as IUdR (24), Ara-A (6, 16), Ara-C (25), and Ara-T (G. A.
Gentry and J. F. Aswell, Fed. Proc. 34:3325, 1975 ) are effective to varying degrees against herpesviruses both in vitro and in vivo. In our present communication we show that a newly available drug, MMUdR, is highly efficacious against HSV-1, and that the lack of toxicity by MMUdR may have advantages over the other nucleoside analogues for treatment of HSV-1 infections in man. Our observation that the antiviral effects of MMUdR was directed only against HSV-1 but not against three other herpesviruses or vaccinia virus is at present not understood. One explanation for the selective action of MMUdR could be that HSV-1 codes for enzymes that are specifically inhibited by this compound.
Although the nucleoside analogues in current use have shown some promise as antiviral agents, their usefulness has been limited because of their toxicity to host cells. Organs with rapidly dividing cells such as the gastrointestinal tract, bone marrow, the fetus, and lymphoid tissue (4, 13, 18, 19, 25) are the usual sites where toxicity is manifest. Our data suggest that the antiviral effects of MMUdR are selectively directed against virus replication and not due to a drastic alteration of the physiological state of host cells. Thus it was shown that MMUdR had no effect on confluent (greater than 500 ,ug/ml) or rapidly dividing cells (greater than 50 jig/ml) in vitro, concentrations far in excess of those inhibitory to virus replication (2 ug/ml). Moreover, pretreatment of cells with MMUdR had no effect on the cells' susceptibility to subsequent virus infection. A calculation of the margin of safety of the respective drugs indicated that MMUdR was much safer to use than any other drug tested. Thus, a computation of the antiviral index determined by dividing the toxic dose by the minimal effective antiviral dose gave values of 250, 80, 40, and 8 for MMUdR, IUdR, Ara-A, and Ara-C, respectively. Recently, MMUdR has also been shown not to have any immunosuppressive effects on lymphoid functions (L. A. Babiuk and B. T. Rouse, submitted for publication). These observations were considered important since recovery from herpesvirus infection probably depends upon an intact lymphoid system (1, 2, 17, 22) . Although the effects of MMUdR on all organs have not been fully investigated, preliminary acute toxicity studies using up to 1,000 mg of MMUdR in adult Swiss mice did not result in mortality nor were any gross lesions or hematological changes observed at 1 week post-administration (unpublished observations). For these reasons MMUdR may prove to be a very useful anti-herpesvirus drug, possibly without the several adverse side effects observed with other nucleoside analogues.
In addition to the problem of toxicity with VOL. 8, 1975 on The nature of the antiviral activity of MMUdR is in need of future definition. The nucleoside IUdR is believed to interfere with virus replication after its nucleotide is incorporated into deoxyribonucleic acid (DNA) (20) . The antiviral activity of Ara-C has been attributed to its ability to impair DNA synthesis of both the host cell and virus, probably by an inhibition ofthe enzyme DNA polymerase by the nucleotide arabinose cytidine 5'-triphosphate (20) , whereas arabinose adenosine 5'-triphosphate inhibits ribonucleotide reductase (24) . The combination chemotherapy experiments reported by Fiala et al. (8) , as well as those discussed in this report, further support the hypothesis that these nucleoside analogues elicit their effects by interfering at different biochemical stages of DNA replication. Thus enhanced antiviral activity was demonstrated with MMUdR in combination with Ara-A, Ara-C, and IUdR. Studies are presently underway to determine the effect of MMUdR on isolated enzymes and on nucleic acid and protein metabolism of normal and infected cells in an attempt to elicit the mechanism(s) whereby MMUdR exerts its antiviral activity.
